Holen Sie sich die Stockscreener-App
5.25
6.08%
-0.34
Handel nachbörslich:
5.25
Schlusskurs vom Vortag:
$5.59
Offen:
$5.42
24-Stunden-Volumen:
172.84K
Relative Volume:
2.22
Marktkapitalisierung:
$147.63M
Einnahmen:
$21.25M
Nettoeinkommen (Verlust:
$-16.05M
KGV:
-8.6066
EPS:
-0.61
Netto-Cashflow:
$-17.14M
1W Leistung:
-19.23%
1M Leistung:
-21.99%
6M Leistung:
+13.64%
1J Leistung:
-51.88%
1-Tages-Spanne:
$5.0987
$5.61
1-Wochen-Bereich:
$5.0987
$6.48
52-Wochen-Spanne:
$3.96
$11.11
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Firmenname
Fennec Pharmaceuticals Inc
Sektor
Branche
Telefon
(919) 636-4530
Adresse
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Vergleichen Sie FENC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
5.25 | 147.63M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-08 | Fortgesetzt | Craig Hallum | Buy |
| 2020-06-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-11 | Eingeleitet | Goldman | Buy |
Fennec Pharmaceuticals Inc Aktie (FENC) Neueste Nachrichten
Vitro Diagnostics (OTCMKTS:VODG) & Fennec Pharmaceuticals (NASDAQ:FENC) Head to Head Survey - Defense World
Fennec Pharmaceuticals (TSE:FRX) Share Price Passes Below 50 Day Moving Average – Should You Sell? - Defense World
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
(FENC) Investment Analysis and Advice - news.stocktradersdaily.com
Fennec Pharmaceuticals Achieves Strong Growth and Expands Market Reach in 2024 - TipRanks
Long Term Trading Analysis for (FRX) (FRX:CA) - news.stocktradersdaily.com
(FRX) Stock Market Analysis (FRX:CA) - news.stocktradersdaily.com
(FENC) Technical Data - news.stocktradersdaily.com
(FRX) Equity Market Report (FRX:CA) - news.stocktradersdaily.com
Q1 EPS Forecast for Fennec Pharmaceuticals Raised by Analyst - Defense World
HC Wainwright Has Positive Forecast for TSE:FRX Q1 Earnings - Defense World
Wedbush Research Analysts Boost Earnings Estimates for FENC - Defense World
What is HC Wainwright’s Forecast for FENC Q1 Earnings? - Defense World
US$12.60: That's What Analysts Think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Is Worth After Its Latest Results - Simply Wall St
Wedbush Boosts Earnings Estimates for Fennec Pharmaceuticals - Defense World
Fennec Pharmaceuticals (FENC) Projected to Post Quarterly Earnings on Thursday - Defense World
Fennec Pharmaceuticals: Strong Growth Potential with PEDMARK’s Market Expansion and Strategic Focus - TipRanks
Fennec Pharmaceuticals (NASDAQ:FENC) Receives Buy Rating from HC Wainwright - Defense World
Fennec Pharmaceuticals Reports Strong Growth Amid Challenges - TipRanks
Fennec Pharmaceuticals: Strategic Market Expansion and Financial Performance Justify Buy Rating - TipRanks
(FRX) Technical Data (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Call Transcript - Insider Monkey
Rhumbline Advisers Grows Holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals (NASDAQ:FENC) Receives “Outperform” Rating from Wedbush - Defense World
Fennec Pharmaceuticals Reports Strong 2024 Sales Growth - TipRanks
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results - TradingView
Earnings call transcript: Fennec Pharmaceuticals Q4 2024 earnings beat forecasts By Investing.com - Investing.com South Africa
Wedbush Reviews Fennec Pharmaceuticals' Q4 -March 10, 2025 at 12:48 pm EDT - Marketscreener.com
Fennec Pharmaceuticals Q4 revenue beats, stock tumbles 16% By Investing.com - Investing.com Canada
Fennec Pharmaceuticals Q4 revenue beats, stock tumbles 16% - Investing.com
Fennec Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Fennec Pharmaceuticals Q4 2024 earnings beat forecasts - Investing.com
Investing in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gain - Yahoo Finance
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Fennec Pharmaceuticals Reports Strong 2024 Financials and Expands Global Reach - TipRanks
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - The Manila Times
FENNEC PHARMACEUTICALS Earnings Results: $FENC Reports Quarterly Earnings - Nasdaq
Earnings Flash (FRX.TO) Fennec Pharmaceuticals Posts Q4 Revenue US$7.925 Million - Marketscreener.com
Fennec Pharmaceuticals Inc Q4 Loss Decreases, Beats Estimates - Nasdaq
Earnings Scheduled For March 10, 2025 - Benzinga
Fennec Pharmaceuticals (FENC) Projected to Post Quarterly Earnings on Monday - Defense World
Fennec Pharmaceuticals director Raykov sells $67,900 in stock By Investing.com - Investing.com Canada
Fennec Pharmaceuticals director Raykov sells $67,900 in stock - Investing.com
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 - The Manila Times
Trading (FENC) With Integrated Risk Controls - Stock Traders Daily
(FRX) Investment Analysis and Advice (FRX:CA) - Stock Traders Daily
Trading (FRX) With Integrated Risk Controls (FRX:CA) - Stock Traders Daily
Chris Anigeron Rallis Sells 1,186 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock - MarketBeat
(FRX) Proactive Strategies (FRX:CA) - Stock Traders Daily
Fennec Pharmaceuticals (TSE:FRX) Stock Passes Above 50-Day Moving AverageHere's Why - MarketBeat
Finanzdaten der Fennec Pharmaceuticals Inc-Aktie (FENC)
Umsatz
Nettogewinn
Free Cashflow
ENV
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):